Ionis Pharmaceuticals and Arrowhead Pharmaceuticals have found a common cause amid their emerging rivalry. | Ionis ...

To get a sense of who is truly in control of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), it is important to understand the ownership structure of the business. We can see that institutions own the ...

Arrowhead Pharmaceuticals Stock Up 0.1 % NASDAQ ARWR opened at $13.82 on Friday. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27. Arrowhead ...

Arrowhead Pharmaceuticals, Inc. shines with 19 clinical programs, strategic partnerships, and promising RNAi data. Click for ...

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) have been given a consensus recommendation of ...

The National Triglyceride Alliance (NTA) is proud to announce its official launch, marking a pivotal step in advancing ...

Try Now>> See today’s best-performing stocks on TipRanks >> Read More on ARWR: Arrowhead Pharmaceuticals NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was generally well tolerated among 14 patients with kidney disease.

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery ...

In trading on Thursday, shares of Arrowhead Pharmaceuticals Inc (Symbol: ARWR) entered into oversold territory, hitting an RSI reading of 29.6, after changing hands as low as $14.87 per share.